Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
117
-
Total 13F shares, excl. options
-
28.1M
-
Shares change
-
+11.4M
-
Total reported value, excl. options
-
$122M
-
Value change
-
+$50.2M
-
Put/Call ratio
-
0.23
-
Number of buys
-
66
-
Number of sells
-
-19
-
Price
-
$4.34
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q4 2024
129 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q4 2024.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 117 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.1M shares
of 66.6M outstanding shares and own 42.2% of the company stock.
Largest 10 shareholders include COMMODORE CAPITAL LP (5.38M shares), BlackRock, Inc. (2.84M shares), Pfizer Inc (2.41M shares), VANGUARD GROUP INC (2.28M shares), ORBIMED ADVISORS LLC (1.54M shares), ACORN CAPITAL ADVISORS, LLC (1.44M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.29M shares), GEODE CAPITAL MANAGEMENT, LLC (983K shares), MAI Capital Management (917K shares), and STATE STREET CORP (849K shares).
This table shows the top 117 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.